PL2646031T3 - Wzrost biodostępności leku w terapii naltreksonem - Google Patents

Wzrost biodostępności leku w terapii naltreksonem

Info

Publication number: PL2646031T3
Authority: PL; Poland
Prior art keywords: drug bioavailability; increasing drug; naltrexone therapy; naltrexone; therapy
Prior art date: 2010-12-03

Application number

PL11845186T

Other languages

English (en)

Inventor

Shawn Flanagan

Eduardo Dunayevich

Original Assignee

Orexigen Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-03

Filing date

2011-12-02

Publication date

2017-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2646031(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-12-02 Application filed by Orexigen Therapeutics, Inc. filed Critical Orexigen Therapeutics, Inc.

2017-08-31 Publication of PL2646031T3 publication Critical patent/PL2646031T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Psychology (AREA)
Acoustics & Sound (AREA)
Physics & Mathematics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicinal Preparation (AREA)

PL11845186T 2010-12-03 2011-12-02 Wzrost biodostępności leku w terapii naltreksonem PL2646031T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41939510P	2010-12-03	2010-12-03

Publications (1)

Publication Number	Publication Date
PL2646031T3 true PL2646031T3 (pl)	2017-08-31

Family

ID=46172304

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL11845186T PL2646031T3 (pl)	2010-12-03	2011-12-02	Wzrost biodostępności leku w terapii naltreksonem
PL21152314.7T PL3884947T3 (pl)	2010-12-03	2011-12-02	Wzrost biodostępności leku w terapii naltreksonem
PL17156985T PL3222280T3 (pl)	2010-12-03	2011-12-02	Wzrost biodostępności leku w terapii naltreksonem

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL21152314.7T PL3884947T3 (pl)	2010-12-03	2011-12-02	Wzrost biodostępności leku w terapii naltreksonem
PL17156985T PL3222280T3 (pl)	2010-12-03	2011-12-02	Wzrost biodostępności leku w terapii naltreksonem

Country Status (26)

Country	Link
US (1)	US20130245056A1 (pl)
EP (4)	EP2646031B9 (pl)
JP (5)	JP6008866B2 (pl)
KR (5)	KR102258043B1 (pl)
CN (1)	CN103313711A (pl)
AR (2)	AR093182A1 (pl)
AU (2)	AU2011336304B2 (pl)
BR (1)	BR112013013390A2 (pl)
CA (2)	CA3239386A1 (pl)
CL (1)	CL2013001564A1 (pl)
CY (2)	CY1118968T1 (pl)
DK (3)	DK2646031T3 (pl)
ES (2)	ES2625527T3 (pl)
FI (1)	FI3884947T3 (pl)
HR (3)	HRP20240115T1 (pl)
HU (3)	HUE065852T2 (pl)
IL (3)	IL226504B (pl)
LT (3)	LT3222280T (pl)
MX (1)	MX356801B (pl)
PL (3)	PL2646031T3 (pl)
PT (3)	PT3222280T (pl)
RS (3)	RS62149B1 (pl)
RU (1)	RU2640561C2 (pl)
SI (3)	SI3884947T1 (pl)
TW (1)	TWI618536B (pl)
WO (1)	WO2012075459A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2316456T1 (sl)	2003-04-29	2017-10-30	Orexigen Therapeutics, Inc.	Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
CN101370488B (zh)	2005-11-22	2012-07-18	奥雷西根治疗公司	增加胰岛素敏感性的组合物
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
JP2011521973A (ja)	2008-05-30	2011-07-28	オレキシジェン・セラピューティクス・インコーポレーテッド	内臓脂肪の状態を処置するための方法
BR112012016783A2 (pt)	2010-01-11	2015-09-01	Orexigen Therapeutics Inc	"usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
PT3222280T (pt) *	2010-12-03	2021-04-22	Nalpropion Pharmaceuticals Llc	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
AU2013271622B2 (en)	2012-06-06	2018-03-01	Nalpropion Pharmaceuticals Llc	Methods of treating overweight and obesity
WO2016125109A1 (en) *	2015-02-07	2016-08-11	Intas Pharmaceuticals Ltd.	Pharmaceutical composition for the treatment of obesity
KR20200072445A (ko) *	2017-03-28	2020-06-22	엘디엔 파마 리미티드	암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제
EP3482751A1 (en) *	2017-11-14	2019-05-15	LDN Pharma Limited	Cancer treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10129265A1 (de) *	2001-06-18	2003-01-02	Hf Arzneimittelforsch Gmbh	Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) *	2002-07-02	2005-12-06	Bernstein Richard K	Method for reducing food intake
EP1772147A2 (en) *	2003-03-17	2007-04-11	Japan Tobacco, Inc.	Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
SI2316456T1 (sl)	2003-04-29	2017-10-30	Orexigen Therapeutics, Inc.	Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
EP1907005A1 (en)	2005-07-27	2008-04-09	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss
US8921344B2 (en) *	2006-11-03	2014-12-30	Salix Pharmaceuticals, Inc.	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN101370488B (zh)	2005-11-22	2012-07-18	奥雷西根治疗公司	增加胰岛素敏感性的组合物
WO2007089318A2 (en)	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
TW200803901A (en)	2005-11-28	2008-01-16	Orexigen Therapeutics Inc	Methods of treating anxiety disorders
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
EP2526932B1 (en) *	2006-06-19	2017-06-07	Alpharma Pharmaceuticals LLC	Pharmaceutical composition
KR101264789B1 (ko)	2006-06-30	2013-05-15	엘지디스플레이 주식회사	횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
WO2008011150A1 (en) *	2006-07-20	2008-01-24	Somaxon Pharmaceuticals, Inc.	Methods of improving the pharmacokinetics of doxepin
KR101735466B1 (ko) *	2006-11-09	2017-05-15	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20090090316A (ko)	2006-11-09	2009-08-25	오렉시젠 세러퓨틱스 인크.	체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
KR20170037676A (ko) *	2007-04-11	2017-04-04	바이오마린 파머수티컬 인크.	테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
DE102007036076A1 (de)	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
WO2009035473A2 (en) *	2007-09-13	2009-03-19	Sanfilippo Louis C	Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
JP2011521973A (ja)	2008-05-30	2011-07-28	オレキシジェン・セラピューティクス・インコーポレーテッド	内臓脂肪の状態を処置するための方法
PT3222280T (pt) *	2010-12-03	2021-04-22	Nalpropion Pharmaceuticals Llc	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona

2011
- 2011-12-02 PT PT171569858T patent/PT3222280T/pt unknown
- 2011-12-02 KR KR1020207011510A patent/KR102258043B1/ko active IP Right Grant
- 2011-12-02 PL PL11845186T patent/PL2646031T3/pl unknown
- 2011-12-02 HU HUE21152314A patent/HUE065852T2/hu unknown
- 2011-12-02 SI SI201132102T patent/SI3884947T1/sl unknown
- 2011-12-02 DK DK11845186.3T patent/DK2646031T3/en active
- 2011-12-02 FI FIEP21152314.7T patent/FI3884947T3/fi active
- 2011-12-02 LT LTEP17156985.8T patent/LT3222280T/lt unknown
- 2011-12-02 HR HRP20240115TT patent/HRP20240115T1/hr unknown
- 2011-12-02 BR BR112013013390A patent/BR112013013390A2/pt not_active Application Discontinuation
- 2011-12-02 ES ES11845186.3T patent/ES2625527T3/es active Active
- 2011-12-02 US US13/991,137 patent/US20130245056A1/en not_active Abandoned
- 2011-12-02 LT LTEP11845186.3T patent/LT2646031T/lt unknown
- 2011-12-02 CA CA3239386A patent/CA3239386A1/en active Pending
- 2011-12-02 AU AU2011336304A patent/AU2011336304B2/en active Active
- 2011-12-02 RU RU2013127423A patent/RU2640561C2/ru active
- 2011-12-02 PL PL21152314.7T patent/PL3884947T3/pl unknown
- 2011-12-02 CN CN2011800638854A patent/CN103313711A/zh active Pending
- 2011-12-02 PT PT211523147T patent/PT3884947T/pt unknown
- 2011-12-02 KR KR1020137017317A patent/KR20140035320A/ko not_active Application Discontinuation
- 2011-12-02 MX MX2013006071A patent/MX356801B/es active IP Right Grant
- 2011-12-02 ES ES17156985T patent/ES2866879T3/es active Active
- 2011-12-02 JP JP2013542229A patent/JP6008866B2/ja active Active
- 2011-12-02 EP EP11845186.3A patent/EP2646031B9/en active Active
- 2011-12-02 SI SI201131199A patent/SI2646031T1/sl unknown
- 2011-12-02 SI SI201131967T patent/SI3222280T1/sl unknown
- 2011-12-02 EP EP21152314.7A patent/EP3884947B1/en active Active
- 2011-12-02 TW TW100144442A patent/TWI618536B/zh active
- 2011-12-02 KR KR1020187016354A patent/KR101984500B1/ko active IP Right Grant
- 2011-12-02 PT PT118451863T patent/PT2646031T/pt unknown
- 2011-12-02 DK DK21152314.7T patent/DK3884947T3/da active
- 2011-12-02 EP EP17156985.8A patent/EP3222280B1/en active Active
- 2011-12-02 HU HUE17156985A patent/HUE053831T2/hu unknown
- 2011-12-02 RS RS20210469A patent/RS62149B1/sr unknown
- 2011-12-02 KR KR1020197014576A patent/KR102105857B1/ko active Application Filing
- 2011-12-02 EP EP23209711.3A patent/EP4349369A3/en active Pending
- 2011-12-02 DK DK17156985.8T patent/DK3222280T3/da active
- 2011-12-02 RS RS20170491A patent/RS56014B1/sr unknown
- 2011-12-02 KR KR1020217015625A patent/KR102391511B1/ko active IP Right Grant
- 2011-12-02 CA CA2819262A patent/CA2819262C/en active Active
- 2011-12-02 RS RS20240196A patent/RS65198B1/sr unknown
- 2011-12-02 HU HUE11845186A patent/HUE034393T2/en unknown
- 2011-12-02 WO PCT/US2011/063177 patent/WO2012075459A1/en active Application Filing
- 2011-12-02 AR ARP110104512A patent/AR093182A1/es not_active Application Discontinuation
- 2011-12-02 PL PL17156985T patent/PL3222280T3/pl unknown
- 2011-12-02 LT LTEP21152314.7T patent/LT3884947T/lt unknown
2013
- 2013-05-23 IL IL226504A patent/IL226504B/en active IP Right Grant
- 2013-05-31 CL CL2013001564A patent/CL2013001564A1/es unknown
2016
- 2016-09-12 JP JP2016177391A patent/JP6456890B2/ja active Active
2017
- 2017-05-16 HR HRP20170734TT patent/HRP20170734T1/hr unknown
- 2017-05-18 CY CY20171100524T patent/CY1118968T1/el unknown
- 2017-06-26 AU AU2017204309A patent/AU2017204309A1/en not_active Abandoned
2018
- 2018-12-19 JP JP2018237245A patent/JP7025319B2/ja active Active
2019
- 2019-11-21 IL IL270841A patent/IL270841A/en unknown
2020
- 2020-12-21 IL IL279626A patent/IL279626A/en unknown
2021
- 2021-04-19 CY CY20211100340T patent/CY1124331T1/el unknown
- 2021-04-19 HR HRP20210618TT patent/HRP20210618T1/hr unknown
- 2021-12-23 AR ARP210103655A patent/AR124500A2/es unknown
2022
- 2022-02-10 JP JP2022019546A patent/JP2022060331A/ja active Pending
2024
- 2024-03-27 JP JP2024051334A patent/JP2024071605A/ja active Pending

Also Published As

Publication number	Publication date
CY1118968T1 (el)	2018-01-10
CA2819262C (en)	2024-05-28
EP3222280A1 (en)	2017-09-27
JP2016210809A (ja)	2016-12-15
LT2646031T (lt)	2017-06-26
AU2011336304B2 (en)	2017-03-30
BR112013013390A2 (pt)	2016-09-06
AR093182A1 (es)	2015-05-27
IL270841A (en)	2020-01-30
ES2625527T9 (es)	2018-09-25
MX356801B (es)	2018-06-13
TW201304780A (zh)	2013-02-01
KR102258043B1 (ko)	2021-05-28
KR102391511B1 (ko)	2022-04-26
EP2646031A1 (en)	2013-10-09
KR20190058702A (ko)	2019-05-29
AU2017204309A1 (en)	2017-07-13
EP3884947B1 (en)	2023-11-15
RU2640561C2 (ru)	2018-01-09
HRP20170734T1 (hr)	2017-08-11
KR20180069089A (ko)	2018-06-22
PL3222280T3 (pl)	2021-11-29
PT3222280T (pt)	2021-04-22
HRP20240115T1 (hr)	2024-06-07
US20130245056A1 (en)	2013-09-19
DK3222280T3 (da)	2021-04-19
RU2013127423A (ru)	2015-01-10
CA2819262A1 (en)	2012-06-07
DK3884947T3 (da)	2024-01-22
ES2866879T3 (es)	2021-10-20
JP6456890B2 (ja)	2019-01-23
EP4349369A2 (en)	2024-04-10
AU2011336304A1 (en)	2013-07-11
JP2024071605A (ja)	2024-05-24
JP7025319B2 (ja)	2022-02-24
JP2013544290A (ja)	2013-12-12
CL2013001564A1 (es)	2014-05-02
EP3222280B1 (en)	2021-01-20
RU2017144631A3 (pl)	2021-04-13
TWI618536B (zh)	2018-03-21
SI3884947T1 (sl)	2024-06-28
IL226504B (en)	2021-01-31
KR20210063473A (ko)	2021-06-01
RU2017144631A (ru)	2019-02-18
KR102105857B1 (ko)	2020-05-04
RS65198B1 (sr)	2024-03-29
EP2646031A4 (en)	2014-04-23
PT2646031T (pt)	2017-05-25
SI2646031T1 (sl)	2017-07-31
PL3884947T3 (pl)	2024-05-06
HUE053831T2 (hu)	2021-07-28
KR20200044158A (ko)	2020-04-28
AR124500A2 (es)	2023-04-05
RS62149B1 (sr)	2021-08-31
LT3222280T (lt)	2021-05-10
HUE065852T2 (hu)	2024-06-28
SI3222280T1 (sl)	2021-11-30
HUE034393T2 (en)	2018-02-28
EP2646031B1 (en)	2017-02-22
IL279626A (en)	2021-03-01
JP2019056004A (ja)	2019-04-11
FI3884947T3 (fi)	2024-01-30
EP3884947A1 (en)	2021-09-29
WO2012075459A1 (en)	2012-06-07
PT3884947T (pt)	2024-02-16
CN103313711A (zh)	2013-09-18
KR101984500B1 (ko)	2019-05-31
ES2625527T3 (es)	2017-07-19
MX2013006071A (es)	2013-10-01
CY1124331T1 (el)	2022-07-22
JP6008866B2 (ja)	2016-10-19
CA3239386A1 (en)	2012-06-07
JP2022060331A (ja)	2022-04-14
LT3884947T (lt)	2024-03-12
EP4349369A3 (en)	2024-05-15
KR20140035320A (ko)	2014-03-21
EP2646031B9 (en)	2018-01-10
DK2646031T3 (en)	2017-05-22
HRP20210618T1 (hr)	2021-09-17
RS56014B1 (sr)	2017-09-29

Publication	Publication Date	Title
IL279626A (en)	2021-03-01	Increasing the bioavailability of a drug in treatment with naltrexone
IL226245A0 (en)	2013-07-31	History
GB2479953B (en)	2015-04-29	Drug delivery device
IL221007A (en)	2016-06-30	Pharmaceutical combinations for antiviral therapy
HK1179542A1 (zh)	2013-10-04	藥物遞送裝置
SG10202001055YA (en)	2020-04-29	Drug delivery device
EP2560624A4 (en)	2014-06-25	THERAPEUTIC FORMULATION TO REDUCE THE SIDE EFFECTS OF MEDICATION
GB201017597D0 (en)	2010-12-01	Drug detection
ZA201208185B (en)	2014-03-26	Intravaginall drug delivery device
EP2564852A4 (en)	2013-10-02	MEDICAMENT TREATING CEREBRAL TUMORS
HRP20141173T1 (hr)	2015-01-30	Medikament koji sadrži miramistin
EP2548580A4 (en)	2013-09-11	PHARMACEUTICAL FOR PSEUDOTRAINING THERAPY
EP2626055A4 (en)	2014-04-16	ACTIVE RELEASE DEVICE
GB201019527D0 (en)	2010-12-29	Redox drug derivatives
GB201006112D0 (en)	2010-05-26	Redox drug derivatives